Clinical Trials
Phase 1b/2 Study of E7386 Plus Lenvatinib in Advanced Endometrial Cancer
Lee et alEClinicalMedicine

In the single-arm, open-label, global phase 1b/2 Study 102 (NCT04008797) dose-expansion cohort, the combination of E7386—an oral inhibitor of the interaction between β-catenin and CREB-binding protein (CBP)—and lenvatinib was evaluated in patients with advanced endometrial cancer whose disease progressed after platinum-based chemotherapy and anti-PD-(L)1 immunotherapy.
A total of 30 patients were enrolled, of whom 16 (53.3%) had previously received lenvatinib. Patients were administered E7386 at 120 mg twice daily plus lenvatinib at 14 mg once daily, which was amended from an initial dose of 20 mg once daily during enrollment. The study's primary endpoint was safety, with secondary endpoints evaluating objective response rate (ORR), duration of response, clinical benefit rate, and progression-free survival per RECIST v1.1.
At the data cut-off, five patients (16.7%) remained on active therapy. The combination demonstrated an overall confirmed ORR of 36.7% (95% CI: 19.9–56.1), comprising one complete response and ten partial responses. Efficacy was notably pronounced in the subgroup of 14 patients without prior lenvatinib exposure, achieving an ORR of 57.1% (95% CI: 28.9–82.3); three patients with prior lenvatinib exposure also experienced confirmed responses.
Regarding safety, all 30 patients experienced treatment-emergent adverse events (TEAEs), with vomiting being the most prevalent overall toxicity (73.3%, n = 22). Grade 3 TEAEs occurred in 19 patients (63.3%), led predominantly by diarrhea (n = 4). TEAEs resulted in the discontinuation of lenvatinib, E7386, or both in two patients. Notably, no grade 4 or 5 toxicities were reported. The study was funded by Eisai Inc., and the dose-optimization phase remains actively enrolling.
Key Takeaways
- In heavily pretreated advanced endometrial cancer progressing on chemotherapy and immunotherapy, E7386 combined with lenvatinib produced an overall confirmed objective response rate of 36.7% (95% CI: 19.9–56.1; 1 complete response, 10 partial responses), which reached 57.1% (95% CI: 28.9–82.3) among lenvatinib-naive patients.
- Grade 3 treatment-emergent adverse events occurred in 63.3% of participants (most commonly diarrhea, n = 4), leading to drug withdrawal in two patients, with no grade 4 or 5 adverse events observed.
Read the original sourceEClinicalMedicine
